These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9299938)

  • 1. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays.
    Junker R; Brandt B; Zechel C; Assmann G
    Clin Chem; 1997 Sep; 43(9):1588-94. PubMed ID: 9299938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls.
    Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
    Eur Urol; 2002 Dec; 42(6):577-82; discussion 582. PubMed ID: 12477653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
    Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
    Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
    Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
    Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
    Maeda H; Arai Y; Okubo K; Aoki Y; Okada T; Maekawa S
    Int J Urol; 1998 Jul; 5(4):343-8. PubMed ID: 9712442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
    Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
    Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and total PSA in the diagnosis of prostate cancer.
    Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
    Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
    Patel D; White PA; Milford Ward A
    BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
    Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
    Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.